Valuation: Resverlogix Corp.

Market Cap 21.74M 15.26M 13.55M 12.67M 11.55M 1.47B 22.04M 153M 59.36M 748M 57.29M 56.05M 2.4B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 108M 75.46M 67.03M 62.68M 57.12M 7.27B 109M 758M 294M 3.7B 283M 277M 11.88B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 day-8.47%
1 week+3.67%
Current month-8.53%
1 month-12.57%
3 months+3.32%
6 months-20.61%
Current year-16.17%
1 week 0.06
Extreme 0.05822
0.07
1 month 0.06
Extreme 0.05822
0.07
Current year 0.05
Extreme 0.0492
0.1
1 year 0.05
Extreme 0.0492
0.1
3 years 0.02
Extreme 0.023
0.21
5 years 0.02
Extreme 0.023
0.65
10 years 0.02
Extreme 0.023
4.14
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Change 5-day change 1-year change 3-year change Capi.($)
-8.47%+3.67% - - 21.74M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.78%-1.14%+24.94%+78.93% 59.26B
+1.50%-0.11%+4.83%+35.22% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.68%+2.92%+29.63%+22.72% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -1.24%-0.52%+52.95%+154.24% 43.6B
Weighted average by Cap. +0.13%-0.32%+58.15%+145.95%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.36M -4.76M -4.45M -4.06M -516M -7.74M -53.84M -20.84M -263M -20.12M -19.68M -844M -7.77M -5.45M -4.84M -4.53M -4.13M -525M -7.87M -54.77M -21.2M -267M -20.46M -20.02M -858M
Net Debt 81.87M 57.45M 51.03M 47.72M 43.49M 5.53B 83M 577M 223M 2.82B 216M 211M 9.05B 85.79M 60.2M 53.47M 50.01M 45.57M 5.8B 86.97M 605M 234M 2.95B 226M 221M 9.48B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
01/10/26 $0.0622 -8.47% 3,133
30/09/26 $0.0680 -1.88% 1,000
25/09/26 $0.0693 +15.50% 610
24/09/26 $0.0600 -6.54% 40,000
23/09/26 $0.0642 +1.26% 23,000